ArticleTherapeutic advances in medical oncology2023

Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer.

Camille Ardin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.